A Phase 1 interventional study of AFA-281 in Pain, Neuropathic and Pain, Inflammatory, sponsored by Afasci Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-21.
Sponsored by Afasci Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.
Among the 291 studies in Neuralgia with a site in United States, this one is the 98th largest by enrollment of the 261 interventional ones that give a count, is one of 17 that started in 2023, is one of 20 in phase 1, and was the 222nd registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 50+
James J. Peters Veterans Affairs Medical Center · Sites in United States
Ages 22+
EicOsis Human Health Inc. · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
291 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 94 · Phase 3 26 · Phase 4 14
First in 1993; this study’s year is marked. 17 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is above the median of 52 across 832 interventional studies indexed under Neuralgia.
Median enrollment 40 across the 261 interventional studies, 53 across the 28 observational. Of the 193 that completed or were terminated, 86 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 291 have an industry lead sponsor. The 10 most frequent:
Afasci Inc is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Afasci Inc has 2 studies filed under Neuralgia — fewer than ten, so there is no comparison to draw.
27 of the studies in Neuralgia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06696443Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | 2027-01-25 |
| NCT07231419Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | 2027-04-06 |
| NCT06628908Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | 2027-05-31 |
| NCT06848348Dogwood Therapeutics Inc.Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | 2026-12 |
| NCT04865679Axogen CorporationTolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends | 2026-12 |
Add all 27 to your calendar (.ics) → With an account.
Among the 291 studies in Neuralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase I Part 1 (single ascending dose):
Double-blind dosing will occur in healthy volunteers in 4 cohorts of 8 subjects each. Six subjects in each cohort will be randomized to receive AFA-281 and 2 subjects will be randomized to receive the matching placebo. At the end of the Part 1 study is to evaluate the safety and tolerability of AFA-281. Following completion of each cohort, bioanalytical analyses will be conducted to evaluate the pharmacokinetic profile.
Phase I Part 2 (multiple dose for 14 days):
Pending the results from Part 1, healthy volunteers will be administered AFA-281 for 14 to 21 consecutive days in 3 cohorts. At scheduled intervals after dosing, and at the end of the cohort's study period to evaluate the safety and tolerability and the pharmacokinetic profile of AFA-281.
Phase I Part 1 (single ascending dose):
Healthy volunteers will be admitted to the clinical research unit on Day -1. There will be five cohorts with 8 subjects per cohort. Six subjects per cohort will receive AFA-281 at one of 4 doses and 2 will receive placebo. Oral capsules will be administered on the morning of Day 1, following a 10-hour fast. Blood draws for assessment of Pharmacokinetic parameters will occur 0.2-1 hr pre-dose and at 0.5-, 1-, 2-, 3-, 4-, 8-, 10, 12-, 16-, 24-, 36-, 48-hr, and up to 72-hr post-dose. Vital signs will be collected at scheduled times following dosing. A 12-lead ECG will be obtained pre-dose and scheduled at 2, 4, 8, 24 hr, and 3- or 4 days post- dose. Various clinical laboratory tests will be drawn on Day -1, within 1 hr prior to dosing, and at scheduled timepoints after dosing while the volunteer is housed in the research center. Subjects of Cohorts 1 - 3 will be released following completion of blood draws and safety assessments up to 48 hours and Cohorts 4 and 5 subjects will return for 72-hour blood draws and Day 4 ECG and safety assessment.
Phase I Part 2 (multiple ascending doses - 14 days):
After assessment of the safety data from the single dose Phase I Part 1, healthy volunteers will be randomized into 3 cohorts with 8 subjects per cohort. Five subjects per cohort will receive AFA-281 and 3 will receive placebo. Oral capsules will be administered in dose titration and split daily dose in fours time daily (QID) for 14 - 21 consecutive days. Routine clinical monitoring will occur as in Part 1. Baseline physical examination, vital signs, clinical lab tests, and ECGs will be performed prior to dosing, at scheduled intervals after dosing, and at the end of the cohort's study period to evaluate the safety and tolerability, and the pharmacokinetic profile of AFA-281. Reports of potential adverse events will be elicited, and vital signs and 12-lead ECG will be measured in a similar manner to Part 1. Similarly, clinical laboratory tests will be drawn prior to and after dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must be in good general health with no significant medical history and have no abnormalities on physical examination at screening and/or before administration of the initial dose of study drug.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double blind placebo control
Drug: AFA-281
Part 1: AFA-281 administered as an oral capsule at 5 dose levels for one day. Part 2: AFA-281 administered as an oral capsule at 3 dose levels twice daily for 14 consecutive days. Doses will be determined after completion of Part 1.
Drug: AFA-281
Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)
Treatment-Related Adverse Events
Number of participants with treatment-related adverse events will be assessed using CTCAE v5.0
Time frame: Predose and Up to 72 hours after dose
Heart rate
Heart rate as one of vital signs will be measured
Time frame: Predose and Up to 72 hours after dose
Body temperature
Body temperature (0C) as one of vital signs will be measured
Time frame: Predose and Up to 72 hours after dose
Blood Pressure
Blood pressure as one of vital signs will be measured
Time frame: Predose and Up to 72 hours after dose
Electrocardiogram (ECG)
Triplicate 12-lead ECG will be measured to evaluate electrical activity of the heart
Time frame: Pre-dose and up to 72 hours after dose
Blood chemistry
Blood chemistry parameters will be measured
Time frame: Pre-dose and up to 72 hours after dose
Hematology
Hematology parameters will be measured
Time frame: Pre-dose and up to 72 hours after dose
Coagulation
Coagulation parameters (PT/INR, PTT) will be measured
Time frame: Pre-dose and up to 72 hours after dose
Urinalysis
Urinalysis parameters will be measured using dipstick and microscopic examination.
Time frame: Pre-dose and up to 72 hours after dose
Blood maximum plasma concentration (Cmax) of the study drug
Pharmacokinetics parameter Cmax will be measured to assess drug exposure levels in blood
Time frame: Pre-dose and up to 72 hours after dose
Blood study drug half-life (t1/2)
Pharmacokinetics parameter t1/2 will be measured to evaluate drug half-life in the blood
Time frame: Pre-dose and up to 72 hours after dose
Area under the plasma concentration versus time curve (AUC) of the study drug
Pharmacokinetics parameter AUC will be measured
Time frame: Pre-dose and up to 72 hours after dose
A dose and exposure relationship
Doses of study drug and blood exposure levels will be analyzed to determine dose proportionality.
Time frame: Pre-dose and up to 72 hours after dose
Tmax of the study drug (parent compound) in blood
Pharmacokinetics parameter Time at which Cmax of the study drug appeared will be determined.
Time frame: Up to 72 hours after dose
Plasma Concentration (Cmax) of the major metabolite in blood
Pharmacokinetics parameter Cmax of a major metabolite will be measured.
Time frame: Up to 72 hours after dose
Area under the plasma concentration versus time curve (AUC) of the major metabolite in blood
Pharmacokinetics parameter AUC of a major metabolite will be measured.
Time frame: Up to 72 hours after dose
The major metabolite half-life (t1/2) in blood
Pharmacokinetics parameter t1/2 of a major metabolite will be measured.
Time frame: Up to 72 hours after dose
Plan to share: Yes — One year after completion of the study and 6 months after publication
Supporting information: Statistical analysis plan, Informed consent form
Time frame: One year after completion of the study and 6 months after publication
Access criteria: To be added
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in Dec 2024, 19 months.
Of 36 phase 1 interventional studies under Neuralgia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 19 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AFA-281
Afasci Inc